Temporal order of clinical and biomarker changes in familial frontotemporal dementia

Nature Medicine · 2022 · 131 citations

• Medicine
• Oncology
• Internal medicine

Utility of the global CDR^® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

Alzheimer s & Dementia · 2020 · 161 citations

• Psychology
• Medicine
• Clinical psychology

INTRODUCTION: plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD. METHODS: The CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants. RESULTS: The CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non-fluent/agrammatic variant primary progressive aphasia participants. DISCUSSION: The global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.